Literature DB >> 3370736

Development of alkylating agent-resistant human tumor cell lines.

B A Teicher1, E Frei.   

Abstract

Survival curves and dose escalation studies of four representative human tumor cell lines exposed to the various alkylating agents are presented. With HN2, at a level of one log of cell kill there was a fivefold range in drug concentration required to achieve this degree of cell kill among the cell lines, from 4.5 microM for the SL6 lung adenocarcinoma to 22 microM for the SW2 small-cell lung carcinoma. Four logs of SCC-25 squamous carcinoma cells were killed by 100 microM CDDP; however, there was only about one log of SL6 cells killed by 500 microM CDDP. To kill one log of G3361 melanoma cells required 24 microM 4-HC and to kill one log of SCC-25 cells required 24 microM, approximately a 16-fold difference. The curves for cell kill by L-PAM appeared to be biphasic, with a break at about 100 microM. There was about a threefold range in drug concentration required to achieve one log of cell kill with L-PAM, from 60 microM in the SCC-25 cell line to 18 microM in the SW2 line. To kill one log of SCC-25 cells required 295 microM BCNU and to kill one log of SW2 cell required 120 microM, about a 2.5-fold difference. The range of maximally tolerated HN2 concentrations were from 1200 microM for the SL6 cell line, 48 times the initial concentration, to 300 microM for the SCC-25 line, 16 times the initial concentration. The G3361 line tolerated the highest level of CDDP, 1900 microM, 48 times the initial concentration. The SCC-25 line, on the other hand, tolerated only 600 microM, 30 times the initial concentration. The SL6 cell line maximally tolerated 36 times the initial concentration of 4-HC (1450 microM), whereas the SCC-25 cell line tolerated only 18 times the initial concentration (720 microM). The G3361 melanoma tolerated 1555 microM, 30 times the initial concentration of L-PAM, and the SCC-25 cell line tolerated 700 microM, 14 times the initial concentration. The SL6 cell line tolerated the highest concentration of BCNU, 4200 microM, 24 times the initial concentration. The SCC-25 cell line tolerated 1450 microM, 8 times the initial concentration. In all cases, the SCC-25 cell line was least able to tolerate exposure to increasing concentrations of alkylating agents. The SL6 and G3361 cell lines showed the greatest tolerance for increasing concentrations of alkylating agents.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370736     DOI: 10.1007/bf00264194

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  53 in total

1.  A dose-response study of resistance of leukemia L1210 to cyclophosphamide.

Authors:  W D DeWys
Journal:  J Natl Cancer Inst       Date:  1973-03       Impact factor: 13.506

Review 2.  Gene amplification in cultured animal cells.

Authors:  R T Schimke
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

Review 3.  Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.

Authors:  F M Schabel; D P Griswold; T H Corbett; W R Laster
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

4.  Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content.

Authors:  K Suzukake; B P Vistica; D T Vistica
Journal:  Biochem Pharmacol       Date:  1983-01-01       Impact factor: 5.858

5.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Authors:  B C Behrens; T C Hamilton; H Masuda; K R Grotzinger; J Whang-Peng; K G Louie; T Knutsen; W M McKoy; R C Young; R F Ozols
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

6.  3,4-Dihydroxybenzylamine: a dopamine analog with enhanced antitumor activity against B16 melanoma.

Authors:  M M Wick
Journal:  J Natl Cancer Inst       Date:  1979-12       Impact factor: 13.506

7.  Role of mathematical modeling in protocol formulation in cancer chemotherapy.

Authors:  A J Coldman; J H Goldie
Journal:  Cancer Treat Rep       Date:  1985-10

8.  Quantitative model for multiple levels of drug resistance in clinical tumors.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1983-10

9.  Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas.

Authors:  J G Rheinwald; M A Beckett
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

10.  Development of methotrexate resistance in a human squamous cell carcinoma of the head and neck in culture.

Authors:  E Frei; A Rosowsky; J E Wright; C A Cucchi; J A Lippke; T J Ervin; J Jolivet; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

View more
  7 in total

1.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 2.  Antibody-directed enzyme prodrug therapy.

Authors:  K D Bagshawe
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

3.  Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.

Authors:  B A Teicher; D Chatterjee; J T Liu; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.

Authors:  D Chatterjee; C J Liu; D Northey; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.

Authors:  E Frei; S A Holden; R Gonin; D J Waxman; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.

Authors:  S E Brooks; T T Korbut; N P Dupuis; S A Holden; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.

Authors:  R A Spooner; F Friedlos; K Maycroft; S M Stribbling; J Roussel; J Brueggen; B Stolz; T O'Reilly; J Wood; A Matter; R Marais; C J Springer
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.